Moberg Pharma’s head of US operations, Steve Cagle, will resign by the end of January 2015.
Steve Cagle has been part of the management team at Moberg Pharma since November 2012.
“I am proud of the achievements during the last two years. We have almost doubled the net sales in the U.S. market and made Kerasal Nail the leading OTC product for nail fungus related problems”, said Steve Cagle in a press release.
“Steve and his team have made an excellent job in growing our U.S. business. Our U.S. sales outpaced the market and grew with 31% in the past 12 months. We have established a leading position in foot care, added additional brands through acquisitions and built a strong sales and marketing team. I would like to thank Steve for his great contribution to Moberg Pharma and wish him success when he pursues new career opportunities”, said Peter Wolpert, CEO of Moberg Pharma AB.
The process to recruit a new head of Moberg’s U.S. subsidiary has been initiated.
